Targeted Opportunity Focus on partnerships around targeted protein degradation platforms and MOPED molecular glue technology to co-develop or license novel degraders for CNS and cancer targets highlighted by SK Life Science Labs' preclinical work and AACR presentations.

Clinical Pipeline Leverage interest from SK Life Science Labs' preclinical data and p300-selective degrader findings to identify potential collaborators or customers seeking PROTAC/heterobifunctional approaches or degradation-based therapies in aggressive solid tumors.

Strategic Fit Position SK Life Science Labs as a partner for AI-driven target identification services and ternary complex modeling capabilities to accelerate discovery timelines for external programs seeking novel degraders in oncology and CNS indications.

Funding & Scale Given revenue in the lower tens of millions and a multi-year trajectory, target strategic alliances or co-development deals with mid to large biotech players looking to augment their degrader expertise without large upfront risk.

Engagement Channels Engage through industry conferences (AACR), emphasize readiness to present preclinical data, and offer collaboration on target discovery, E3 ligands/linkers, and MOPED platform licensing to accelerate external program breakthroughs.